TRT Questions Answered by Urologists: 1.3 Million People Want to Know
Dr. Rena Malik, a board-certified urologist, hosts a Q&A format video on testosterone replacement therapy that has resonated with 1.3 million viewers. The appeal is clear: TRT has moved from a niche medical treatment to a mainstream health topic, and the gap between what men hear from online wellness influencers and what they hear from their urologist creates confusion that a straightforward, expert-led Q&A directly addresses. The questions covered here are the ones that fill clinic waiting rooms and online forums alike.
Before diving into the Q&A, it is worth knowing why urologists are particularly well-suited to discuss TRT. The male reproductive system falls within urology's scope of practice. Urologists manage conditions that affect testosterone production (hypogonadism, testicular disorders), are trained in the hormonal axis that regulates testosterone (the hypothalamic-pituitary-gonadal axis), and handle the downstream effects of both low testosterone and its treatment (fertility, prostate health, sexual function). When an endocrinologist and a urologist discuss TRT, they bring complementary perspectives, but for the practical questions most men ask, urology provides the most direct expertise.
Who Actually Needs TRT?
The threshold question that Dr. Malik addresses first is fundamental: how do you know if you actually need testosterone replacement? The answer involves both lab values and symptoms, and neither alone is sufficient. A man with a testosterone level of 250 ng/dL who feels energetic, maintains muscle mass, has normal libido, and sleeps well does not necessarily need TRT. Conversely, a man with a level of 350 ng/dL who is exhausted, losing muscle despite training, has no sex drive, and cannot think clearly may benefit from treatment.
The clinical definition of hypogonadism requires both low testosterone levels (generally below 300 ng/dL total testosterone, though some guidelines use 264 ng/dL) and the presence of symptoms attributable to low testosterone. The symptoms most commonly associated with low T include fatigue not explained by other causes, reduced libido, erectile dysfunction, loss of muscle mass or strength, increased body fat (particularly abdominal), depressed mood, difficulty concentrating, and reduced bone density.
Dr. Malik emphasizes that testosterone testing should follow specific protocols. Blood should be drawn in the morning (testosterone peaks between 7-10 AM and declines throughout the day), and low results should be confirmed with a second test on a different day. A single low reading can result from poor sleep the night before, recent illness, stress, or simply normal variation. Two morning measurements below the threshold, combined with symptoms, establish the diagnosis.
The Most Common Questions Patients Ask
The format of the video covers specific patient questions, and several stand out for their relevance. The fertility question is critical for younger men considering TRT. Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal (HPG) axis through negative feedback. The pituitary, detecting adequate testosterone in the blood, reduces its production of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). Without adequate FSH, sperm production drops dramatically. Many men on TRT become functionally infertile within months of starting treatment.
For men who want to preserve fertility while addressing low testosterone, alternatives exist. Clomiphene citrate (Clomid) works by blocking estrogen receptors in the hypothalamus, tricking the brain into thinking estrogen is low and increasing GnRH, LH, and FSH output. The result is increased testicular testosterone production alongside maintained (or increased) sperm production. Human chorionic gonadotropin (hCG) directly stimulates the Leydig cells in the testes to produce testosterone while maintaining testicular size and some degree of spermatogenesis.
The prostate cancer question generates significant anxiety. The historical concern was that testosterone "feeds" prostate cancer, based on the observation that castration (eliminating testosterone) causes prostate tumors to shrink. However, the relationship between TRT and prostate cancer has been substantially revised over the past two decades. Current evidence does not support the idea that TRT causes prostate cancer in men without existing disease. Men with active or untreated prostate cancer should not receive TRT, but for men with no history of prostate cancer, the risk does not appear to be elevated by TRT.
Cardiovascular risk is another area where understanding has evolved. Early studies raised concerns about TRT increasing cardiovascular events. More recent and larger studies, including the TRAVERSE trial published in 2023, have provided reassurance that TRT at appropriate doses does not increase the risk of major cardiovascular events in men with hypogonadism and existing cardiovascular risk factors. The previous concerning findings may have reflected differences in patient populations, dosing, and monitoring rather than a true causal risk from TRT itself.
Practical Aspects of Starting TRT
Dr. Malik covers the practical details that men contemplating TRT need to understand. Delivery methods include intramuscular injections (typically testosterone cypionate or enanthate, administered weekly or every two weeks), transdermal gels or creams (applied daily to the skin), subcutaneous pellets (implanted under the skin every 3-6 months), and transdermal patches. Each method has trade-offs in terms of convenience, consistency of blood levels, cost, and side effect profile.
Injections provide the most control over dosing and produce the most predictable blood levels. Cypionate and enanthate have half-lives of approximately 8 days, making weekly injections ideal for maintaining stable levels. Every-two-week dosing, while sometimes prescribed for convenience, creates larger swings between peak and trough levels that some men find unpleasant (mood swings, energy fluctuations, acne near peak levels).
Gels and creams offer the convenience of daily topical application without needles. The downside is transfer risk: testosterone applied to the skin can transfer to partners, children, or pets through skin contact, potentially causing virilization in women and children or hormonal disruption in animals. Application sites must be covered, and hands must be washed thoroughly after application. Absorption can also vary based on skin condition, sweating, and application site, making blood level monitoring particularly important.
Monitoring and Long-Term Management
Regular monitoring is non-negotiable during TRT. The standard monitoring panel includes total testosterone (to verify adequate replacement), free testosterone, estradiol (estrogen levels can rise during TRT due to aromatization of testosterone), hematocrit (TRT stimulates red blood cell production, and elevated hematocrit increases blood viscosity and clot risk), PSA (prostate-specific antigen, screened annually), and a complete metabolic panel.
Hematocrit monitoring deserves special attention because it represents one of the most significant ongoing risks of TRT. Testosterone stimulates erythropoiesis (red blood cell production) in the bone marrow. While a mild increase in red blood cells is normal and well-tolerated, significant elevation of hematocrit above 54% increases blood viscosity and the risk of thromboembolic events (blood clots). Men with elevated hematocrit may need to reduce their testosterone dose, donate blood (which temporarily reduces hematocrit), or in severe cases, discontinue TRT.
Estradiol management is another practical consideration. Testosterone is converted to estradiol by the enzyme aromatase, which is particularly active in adipose (fat) tissue. Men with higher body fat percentages tend to produce more estradiol during TRT, potentially causing gynecomastia (breast tissue growth), water retention, mood changes, and reduced libido. Aromatase inhibitors like anastrozole can be used to manage elevated estradiol, though there is growing debate about the appropriate level of intervention, as estradiol also provides cardiovascular and bone health benefits that should not be unnecessarily suppressed.
When to Consider Stopping TRT
Dr. Malik addresses the exit strategy, a topic many men do not think about when starting TRT. Stopping TRT after months or years of use means the HPG axis must restart, and this process can be slow and uncomfortable. During TRT, the pituitary reduces or stops producing LH and FSH because exogenous testosterone provides negative feedback. When TRT stops, it takes time for the hypothalamus and pituitary to resume adequate signaling, and during this gap, testosterone levels can drop well below pre-treatment levels.
For men who need to stop TRT (fertility goals, side effect management, personal choice), a tapering protocol with supportive medications can smooth the transition. Clomiphene citrate or hCG can be used during the transition period to stimulate endogenous testosterone production while the HPG axis recovers. Recovery time varies from weeks to months, and some men, particularly those who had very low pre-TRT levels, may never fully recover their baseline production.
The decision to start TRT should include an honest assessment of whether you are willing to potentially remain on it long-term. Many men who start TRT and experience significant improvement in symptoms choose to continue indefinitely. Understanding this likely trajectory before starting is important for making an informed decision.
Dr. Malik concludes with practical advice about choosing a TRT provider. The ideal provider is someone who specializes in male hormonal health (urologists, endocrinologists, or specially trained primary care physicians), who orders thorough baseline labs before starting treatment, who monitors regularly with appropriate blood work, who is willing to adjust protocols based on both lab values and symptoms rather than rigidly adhering to one approach, and who discusses the full range of options including lifestyle optimization rather than immediately reaching for the prescription pad. Men should be cautious of providers who prescribe TRT without checking baseline LH, FSH, and prolactin (which could reveal a pituitary tumor or other treatable cause), who do not discuss fertility implications, or who fail to monitor hematocrit after starting treatment. The quality of medical oversight directly affects both the safety and effectiveness of TRT over the long term.